Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. Methods: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. Results: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (<12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p<0.001; HR 3.34, p<0.001; and HR 1.74, p=0.006; respectively). Conclusions: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy.
Abstract
Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. Methods: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. Results: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (<12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p<0.001; HR 3.34, p<0.001; and HR 1.74, p=0.006; respectively). Conclusions: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy.
참고문헌 (32)
- El-Serag HB, "Hepatocellular carcinoma : an epidemiologic view", J Clin Gastroenterol, 35(5 Suppl 2), pp.S72~S78 (2002)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Zeuzem S, "Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection : a randomized trial", Ann Intern Med, 163, pp.1~13 (2015)
- Kowdley KV, "Eight weeks of ledipasvir", sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection, 2017, pp.65, 1094~1103
- Pol S, "Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients", J Hepatol, 66, pp.39~47 (2017)
- Luetkemeyer AF, "12 Weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection(ALLY-2Study) : efficacy and safety by HIV combination antiretroviral regimens", Clin Infect Dis, 62, pp.1489~1496 (2016)
- Fried MW, "Treatment of chronic hepatitis C infection with peginterferons plus ribavirin", Semin Liver Dis, 24, pp.47~54 (2004)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C : a randomised trial", Lancet, 358, pp.958~965 (2001)
- Lawitz E, "Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis", Gastroenterology, 149, pp.971~980 (2015)
- Charlton M, "Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease", Gastroenterology, 149, pp.649~659 (2015)
- "Hepatitis C" (2020)[URL]
- Soria A, "Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with directacting antivirals", Hepatology, 66, pp.992~994 (2017)
- Beste LA, "Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma", J Hepatol, 67, pp.32~39 (2017)
- Prenner SB, "Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with directacting antivirals", J Hepatol, 66, pp.1173~1181 (2017)
- Conti F, "Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals", J Hepatol, 65, pp.727~733 (2016)
- Reig M, "Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy", J Hepatol, 65, pp.719~726 (2016)
- Yang JD, "Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma", J Hepatol, 65, pp.859~860 (2016)
- Waziry R, "Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy : a systematic review, meta-analyses, and meta-regression", J Hepatol, 67, pp.1204~1212 (2017)
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- Abergel A, "Chronic hepatitis C : burden of disease and cost associated with hospitalisations in France in 2012(The HEPC-LONE study)", Clin Res Hepatol Gastroenterol, 40, pp.340~348 (2016)
- Ford MM, "Neighborhood inequalities in hepatitis C mortality : spatial and temporal patterns and associated factors", J Urban Health, 94, pp.746~755 (2017)
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Saraiya N, "Systematic review with meta-analysis : recurrence of hepatocellular carcinoma following direct-acting antiviral therapy", Aliment Pharmacol Ther, 48, pp.127~137 (2018)
- Singal AG, "Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study", Gastroenterology, 156, pp.1683~1692 (2019)
- Chiba T, "Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis", J Gastroenterol, 31, pp.552~558 (1996)
- Kanwal F, "Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents", Gastroenterology, 153, pp.996~1005 (2017)
- Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Prenner S, "Reply to : "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma"", J Hepatol, 68, pp.213~214 (2018)
- Saberi B, "et al Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma", Hepatology, 66, pp.661~663 (2017)
- Prenner SB, "Hepatocellular carcinoma in the waitlisted patient with hepatitis C virus", Curr Opin Organ Transplant, 23, pp.237~243 (2018)